ARRY-502

• Description :

  ARRY-502 is an orally active, potent and selective CRTh2 antagonist. ARRY-502 blocks PGD2-mediated Th2 inflammation (e.g., eosinophil activation, airway hyperresponsiveness) . ARRY-502 is promising for research of Th2-related asthma[1].

• UNSPSC :

  12352005

• Target :

  Prostaglandin Receptor

• Related Pathways :

  GPCR/G Protein

• Field of Research :

  Inflammation/Immunology

• Smiles :

  OC([C@@H]1C2=CC(Cl)=C(OC3=CC=C(C=C3)C(NCCC4=C(C=C(C=C4)Cl)OC)=O)C=C2OCC1)=O

• Molecular Formula :

  C26H23Cl2NO6

• Molecular Weight :

  516.37

• References & Citations :

  [1]Wenzel S E, et al. Safety and efficacy of ARRY-502, a potent, selective, Oral CRTh2 antagonist, in patients with mild to moderate Th2-driven asthma[J]. Journal of Allergy and Clinical Immunology, 2014, 133 (2) : AB4.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 4

• CAS Number :

  [1202891-16-4]